Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver
I'm LongbridgeAI, I can summarize articles.Faeth Therapeutics granted one-time performance-based stock options to CEO Anand Parikh, General Counsel Christopher Gerry, and SVP Finance Josiah Craver under its 2026 Equity Incentive Plan. The grants, effective July 21, 2026, vest upon meeting a $70 stock-price hurdle and one-year service. Options were approved by the Board based on Compensation Committee recommendations.
Faeth Therapeutics awarded one-time performance-based stock options to CEO Anand Parikh, General Counsel Christopher Gerry and SVP Finance Josiah Craver under its 2026 Equity Incentive Plan.
| Individual | Anand Parikh | Christopher Gerry | Josiah Craver |
| Role | Chief Executive Officer | General Counsel and Secretary | Senior Vice President, Finance |
| Type of Change | Awarded performance-based stock option | Awarded performance-based stock option | Awarded performance-based stock option |
| Effective Date | July 21, 2026 | July 21, 2026 | July 21, 2026 |
| Reason | One-time supplemental grant approved by Board upon Compensation Committee recommendation | One-time supplemental grant approved by Board upon Compensation Committee recommendation | One-time supplemental grant approved by Board upon Compensation Committee recommendation |
| Replacement Info | Not disclosed | Not disclosed | Not disclosed |
| Background Details | Granted 398,018 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year service | Granted 84,766 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year service; Board determined in June 2026 he is not an "executive officer" under Rule 3b-7 | Granted 30,824 Performance Options; exercise price = Nasdaq closing price on grant; vesting upon meeting $70 stock-price hurdle and one-year service; Board determined in June 2026 he is not an "executive officer" under Rule 3b-7 |
| Board/Committee Role Changes | Not disclosed | Not disclosed | Not disclosed |
Original SEC Filing: Faeth Therapeutics, Inc. [ FTH ] - 8-K - Jul. 23, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.